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Abstract	Cryptococcosis is a serious environmentally acquired endemic fungal infection commonly associated
with immunocompromised hosts. Little is known regarding frequency or distribution in Wisconsin. We
explored the geodemographic and clinical features of patients tested with cryptococcal antigen tests
(CrAg) — previously shown to be >90% sensitive and >90% specific — within a large health care
system located in eastern Wisconsin. To examine this, we retrospectively analyzed 1465 CrAg tests on
1211 unique patients (female: 50.2%; white race: 73.9%; mean age: 53.7 ± 16.5 years). At least one
CrAg result was positive in 23 of 1211 patients (1.9%). From these, 21 of 23 were immunocompromised.
Positive patients were disproportionately male (82.6%) and nonwhite (3.8% of those tested vs 1.2%
of whites tested); P<0.01 for both. These associations remained in multivariable models. Positive
patients were not significantly older (59.1 vs 53.6 years; P=0.07). Overall, 17 separate zip codes had
at least one positive case. Positive patients were more prevalent in the zip codes that included the city
of Milwaukee (11 of 377 [2.9% of those tested] vs 12 of 834 [1.4% of all those tested in the remaining
area of the state]), but this difference was not statistically significant. No other case clustering or
close proximity to waterways was observed (41% were <162 m from green space, similar to historical
controls). Overall, male sex, nonwhite race/ethnicity, and immunocompromised status, not zip code,
were statistically associated with positive CrAg. (J Patient Cent Res Rev. 2020;7:57-62.)
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C

ryptococcosis is a potentially serious
endemic fungal infection.1 The two major
human-pathogenic species (often distinct
geographically) are Cryptococcus neoformans and
Cryptococcus gattii. Risk factors for disease include
exposure to an environmental source of the organism.
Environmental associations of these fungal species
include certain trees and soils, potentially influenced by
certain climatic or anthropic factors (and bird guano for
C. neoformans).1-7 Cryptococcus-related environments
may include common human-frequented sites of
potential exposure like urban parks.7 Except for the
recently proposed association with the oral cavity,8,9 these
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organisms are not part of the human microflora, but they
may cause asymptomatic infection or colonization.1
Cryptococcus fungus enters the body through
inhalation.1 The potential for infection increases
markedly for people affected by acquired immune
deficiency syndrome (AIDS) or in various
immunocompromised states resulting from cancers and
their treatments, corticosteroid therapy, and pediatric
innate immune defects.1,10 Similarly, incidence
rates appear to be proportional to the percentage of
individuals in a population with inadequately treated
AIDS or other immunocompromising conditions.1
In fact, epidemiologic data from the World Health
Organization suggest that nearly 8000 cases of
opportunistic cryptococcal meningitis infection occur
each year among HIV-infected individual in North
America, resulting in an average of 700 annual deaths.11
www.aurora.org/jpcrr
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Cryptococcal infection is often readily demonstrated
by microscopic examination, culture, or cryptococcal
antigen detection test (CrAg). The latter not only
allows for simple, rapid, and low-cost testing for the
diagnosis but is reportedly more than 90% sensitive
and 90% specific for disease.1 In some cases, a CrAg of
blood or cerebrospinal fluid will be positive before the
fungus is demonstrated in culture.1,12 Unfortunately,
the CrAg cannot distinguish between the two humanpathogenic Cryptococcus species.13 This may become
important regionally, given the 4 identified isolates of
C. gatti in the Midwest.14
To our knowledge, nothing has been reported in the
literature regarding the frequency or distribution of
cryptococcosis in Wisconsin since the 1960s.15 The
aims of this study were to explore the geodemographic
features of eastern Wisconsin patients for whom CrAg
was performed and examine the clinical features of
those who tested positive for cryptococcal infection.

METHODS

A retrospective review of electronic medical record
(EMR) data from the affiliated laboratory of a large,
integrated health system spanning eastern Wisconsin

and northeastern Illinois, which houses medical
records of more than 1.2 million unique patients,
was conducted. This area contains the majority of
Wisconsin’s urban and suburban population. Subjects
were all inpatients and outpatients who had CrAg from
January 2013 to April 2017.
The laboratory used the latex agglutination-modeled
Remel™ Cryptococcus Antigen Test Kits (Thermo
Scientific, Lenexa, KS) for the detection of antigen.
Patients with 1 or more positive CrAg were always
considered positive, and patient demographic features
(Table 1) were used from the first identified positive
test. For patients with multiple negative CrAg results,
data were taken from the first test. In addition, for
comparison of individuals with any positive CrAg
to those with negative CrAg, a manual EMR review
of all CrAg-positive patients and the first 700 CrAgnegative patients, alphabetically, was performed.
This comparison examined immunocompromising
conditions listed in the EMR and type of clinical
presentation prior to obtaining CrAg.
Fisher exact test or t-test was used for univariable
comparisons between patients with at least one

Table 1. Demographic Features of Subjects by Cryptococcal Antigen Test (CrAg) Result
Positive CrAg
n=23

Negative CrAg
n=1188

Total
N=1211a

P

59.1 ± 13.5

53.6 ± 16.6

53.7 ± 16.5

0.066

Female

4 (0.7%)

603 (99.3%)

607 (50.2%)

Male

19 (3.2%)

584 (96.8%)

603 (49.8%)

White

11 (1.2%)

883 (98.8%)

894 (73.9%)

Black

7 (4.5%)

149 (95.5%)

156 (12.9%)

0.011c

Hispanic

3 (2.8%)

103 (97.2%)

106 (8.8%)

0.178c

Asian

2 (5.9%)

32 (94.1%)

34 (2.8%)

0.079c

Native American

0 (0.0%)

6 (100.0%)

6 (0.5%)

1.000c

Unknown

0 (0.0%)

14 (100.0%)

14 (1.2%)

1.000c

All nonwhite

12 (3.8%)

304 (96.2%)

316 (26.1%)

0.002c

Characteristic
Mean age, years ± SD
Sex, n (%)

0.007b

Race/Ethnicity, n (%)

a

Due to missing data, total number for sex and race/ethnicity categories was 1210.

b

Compared to CrAg-positive females (Fisher exact test).

c
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Compared to CrAg-positive whites (Fisher exact test).
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positive CrAg test and those who only tested negative.
Stepwise and binary logistic regression were used for
multivariable analysis.
Approval for this study was obtained from the local
institutional review board. Note that this study is not a
population-based survey, nor an analysis of cliniciandiagnosed cryptococcosis, but rather a dissection of
patients with clinician-ordered CrAg in one health
system.

RESULTS

A total of 1465 unique CrAg tests (741 on serum, 723
on cerebrospinal fluid, 1 other specimen), including
multiple tests on the same patient, were performed
on 1211 unique patients during the study period. The
CrAg-tested study population was 50.2% female,
73.9% white, and had a mean age of 53.7 years
(standard deviation: 16.5 years) (Table 1).
At least one CrAg was positive in 23 of 1211
(1.9%) patients. Of these 23 individuals, 21 were
immunocompromised
(6
transplant
patients,
5 with HIV, 4 with malignancy, 3 had chronic
corticosteroid use, 2 with diabetes mellitus, and 1
with combined immunodeficiency). Further detailed
analysis of all positive patients plus the first 700
negative patients (n=723) revealed that 58.2% had
an immunocompromising condition listed. Of those
patients with an immunocompromised condition, 53.5%
had only a central nervous system (CNS) presentation,
23.2% had only a pulmonary presentation, 7.9% had both
presentations, and 15.4% had neither presentation. Based
on 58.2% having immunocompromising condition, 13
of 23 immunocompromised patients would have been
predicted to test positive; in reality, 21 did (P<0.001).

C. gattii (our microbiology laboratory did not routinely
differentiate the species at the time of this study). Of
the 2 patients without apparent immunodeficiency, 1
had confirmed disseminated cryptococcosis. The other
patient had an otherwise unexplained pneumonia;
however, fungal culture was not done, and a
Cryptococcus serum antibody titer was low (1:2).
CrAg-positive patients were disproportionately male
(19 of 23 [3.2% of all males tested] vs 4 of 23 female
[0.7% of all females tested]; P=0.002) and nonwhite
(12 of 23 [3.8% of all nonwhite patients tested] vs
11 of 23 white [1.2% of all white patients tested];
P=0.007). These associations remained significant in a
multivariable binary regression model (Table 2). In the
723-patient subcohort that included all 23 positive cases
and 700 negative cases, detailed immune status data
in the EMR was available for 678 patients. A stepwise
regression model based on this population revealed that
male sex, nonwhite race, and immunocompromised
state remained significantly associated with positive
CrAg result (P<0.02 for all).

Table 2. Multivariable Binary Regression Model of

Demographics Associated With Positive Cryptococcal
Antigen Test (n=1210)
Characteristic
Male gender
Nonwhite

Odds Ratio

95% CI

P

5.00
3.18

1.67–14.29
1.38–7.31

0.007
0.002

Overall, 7 CrAg-positive patients were diagnosed with
cryptococcal meningitis, and 2 additional patients
had cerebrospinal fluid that tested CrAg-positive.
Six patients were diagnosed with disseminated
cryptococcosis; 3 patients had a pulmonary presentation
(but no diagnosis); 1 patient had a combined pulmonary
and CNS presentation but died before precise diagnosis
could be established; and 4 patients had CrAg-positive
serum but no recorded cryptococcosis diagnosis.

The geographic distribution of patients with positive
CrAg in the eastern Wisconsin catchment area is
illustrated in Figure 1. Overall, 17 separate zip codes
had 1 positive case; 2 city of Milwaukee zip codes had
3 each, the closest two living 193 meters apart. No
other CrAg-positive case clustering or close proximity
to waterways was observed; 41% were less than 162
m (ie, <0.1 miles) from green space (parks/farms/
forests). Positive patients were more prevalent in the
532xx zip codes that include Milwaukee (11 of 377
[2.9% of those tested] vs 12 of 834 [1.4% of all those
tested in the remaining catchment area of the state]),
but this difference was not significant (P=0.176).

Of the 18 CrAg-positive patients with a recorded
fungal culture, 17 were positive for C. neoformans or

Further examining the 678 Wisconsin patients with
detailed immune status data in the EMR, 144 of 233
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Figure 1. Map of zip code location of individuals with positive cryptococcal antigen tests. Panels show, from

left to right, state of Wisconsin, eastern Wisconsin catchment area, and magnified view of Milwaukee County.
Overall, 17 separate zip codes contained 1 positive case (shaded in green); 2 city of Milwaukee zip codes had
3 each (shaded in red).

in Milwaukee zip codes (61.8%) were noted to be
immunocompromised compared to 251 of 445 in
the rest of Wisconsin zip codes (56.4%; P=0.190).
Similarly, examining the 17 zip codes with 1 or
more CrAg-positive cases (all in Wisconsin, none in
northeastern Illinois), tested individuals were more
likely to be immunocompromised compared with
those from zip codes without a positive case (88 of 133
[66.2%] vs 307 of 545 [56.3%], P=0.040). Indeed, 18
of 25 total CrAg-tested individuals residing in the pair
of Milwaukee zip codes that each had 3 CrAg-positive
cases were noted to be immunocompromised.

DISCUSSION

The incidence of cryptococcosis is not well known
in the United States, as it is not a reportable disease
in many states.16 Limited data suggest an overall
incidence of 0.4–1.3 cases/100,000 annually, and a
2.9% prevalence of cryptococcal antigen in serum
of patients with HIV and low CD4 counts.16 Thus, it
seems that our CrAg-positive rate (1.9%) is consistent
with national statistics given a tested population
with half or more having an immunocompromising
condition and with cryptococcosis in the differential
diagnosis. A hospital discharge-based survey of 18
states, including Wisconsin, indicated a 1997–2009
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cryptococcal meningitis hospitalization rate of <2
per 1 million population for HIV-infected individuals
and 2–4 per 1 million rate for those without HIV.17
Extrapolating our data and considering 1.2 million
patients in our health system at the time of the study,
we would estimate 3 per 1 million persons have CNSbased Cryptococcus infections indicated by CrAg, per
year, a figure consistent with those reported numbers.
Serum CrAg may be falsely negative in patients with
pulmonary cryptococcosis unless the disease has
disseminated.18 Thus, the 3 patients who had only a
pulmonary presentation in our study may underestimate
this manifestation in our population. Pulmonary
cryptococcosis may spread to the CNS, worsening the
prognosis of an already serious disease but increasing
the likelihood of detection.18
The preponderance of male patients with positive
CrAg is consistent with previous literature.1 This
elevated male cryptococcosis prevalence predates the
HIV outbreak and may be due to gender differences
in macrophage response to Cryptococcus.19 A sample
of the wide variety of reported immunocompromising
conditions predisposing to cryptococcosis was seen in
our study.1,17,18
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The proportion of CrAg-positive patients in our study
who were within 162 m (<0.1 miles) from green space
(41%) was similar to a historical control group of 250
randomly selected adult patients with communityacquired pneumonia taken from this same catchment
area (39.6%) for a 2006–2013 blastomycosis study.20
Our data suggest that Wisconsin zip codes having
1 or more patients with positive CrAg contained a
higher proportion of individuals considered to be
immunocompromised and that the higher proportion of
individuals with positive CrAg in and near Milwaukee
reflect this fact. Taken together, perhaps this suggests
that the proportion of persons in a given eastern
Wisconsin locale who are immunocompromised
has more influence on the incidence of cryptococcal
infections than does any geographic feature. Further
research is required to test this hypothesis.
Interestingly, recent molecular studies indicate
that Cryptococcus species may be members of the
human oral microbiota in some individuals.8,9 It
has been suggested that oral carriage could lead
to opportunistic cryptococcal infections.8 We are
currently undertaking a culture-based study to
determine if pathogenic Cryptococcus species indeed
reside within the human oral cavity. If this proves
to be the case, the path to cryptococcal infection in
some persons could be a two-step process, first from
the environmental source to oral colonization, then
spreading to other organ systems.
The limitations of this descriptive study are those
inherent to a retrospective EMR review in a single
health system. Therefore, statistical comparisons must
be interpreted with caution pending further research.
We included performance of CrAg as the sole entry
criteria for the study and did not base the comparison of
positive and negative cases on additional confirmation
such as culture.
In addition, CrAg does not distinguish between C.
neoformans and C. gattii. This distinction may be
clinically important, as there was some evidence that the
latter may lead to more pulmonary and CNS morbidity
than the former and may require longer treatment.21 C.
gattii appears to commonly infect normal hosts; however,
it is recognized as also causing serious disease in HIV-
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infected persons.22 In addition to the known endemicity
of C. gattii in Washington and Oregon, this species is
now being recognized in other regions of the United
States, including the southeast,22 where it may have been
present for several thousand years.23 C. gattii is likely
present in the environment just south of southeastern
Wisconsin, meaning it may be endemic to the catchment
area of our study.14 Initial attempts to culture C. gattii
from natural environments in Wisconsin have been
unsuccessful.24 There is need for routine testing to
differentiate between both Cryptococcus species and to
increase clinician awareness of the nuances regarding C.
neoformans and C. gattii.22

Patient-Friendly Recap
• Cryptococcosis is a fungal infection acquired
through inhalation from the environment. It can
cause meningitis, pneumonia, or widespread
damage to cells and body tissue, usually in
people with weakened immune systems.
• The authors identified cases of cryptococcal
infection contracted by people living in eastern
Wisconsin and studied the characteristics
of these individuals and features of their
respective zip codes.
• They found that among patients testing
positive for cryptococcosis, male sex,
nonwhite race/ethnicity, and a weakened
immune system — but not geographic features
such as proximity to water — were associated
with having a positive test.
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